Actelion Stresses Importance of PAH Early Detection, Life Quality at 2016 SSc World Congress and in Exclusive Interview

Author: Patricia Silva
Date Published: February-2016
Source: Scleroderma News

New data was recently presented regarding Actelion Pharmaceuticals’ therapies and strategies to improve clinical outcomes in patients with pulmonary arterial hypertension (PAH). The data were presented at the Actelion Satellite Symposium, titled “Improving outcome in pulmonary arterial hypertension,” which was part of the 4th Systemic Sclerosis World Congress held in Lisbon, Portugal, on Feb. 18-20, 2016.